Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2020-05-14 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2020-05-14 English
Interim MD&A - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Rebel Capital 2.0 Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2020. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3018 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-05-14 English
Interim MD&A - English.pdf
Regulatory Filings
2020-05-14 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-05-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2020. The document does not contain actual financial data or substantive financial analysis but is an officer certification related to interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 2980 characters, which is relatively short and consistent with a certification letter rather than a full report.
2020-03-10 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Alphanco Venture Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2020. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is under 5,000 characters and is a certification, not the report itself.
2020-03-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.